Product Type Segment Analysis: Consumables (Largest Segment) vs Instruments/Analyzers (Fastest-Growing Segment)

The consumables product type segment dominated the CT/NG testing market, accounting for 71.9% in 2026. Its leading position is primarily attributed to the recurring use of test kits, reagents, assay components, and other disposable materials required for routine sexually transmitted infection screening and diagnosis. The increasing volume of diagnostic testing, coupled with the need for consistent testing accuracy and uninterrupted laboratory operations, continues to generate sustained demand for consumables. Their essential role in every testing procedure ensures repeated purchasing across healthcare facilities and diagnostic laboratories.

The instruments/analyzers product type segment is expected to witness the fastest growth as healthcare providers increasingly invest in automated diagnostic platforms that improve testing efficiency, reduce turnaround times, and support higher sample throughput. Technological advancements in molecular diagnostics and laboratory automation are encouraging the replacement of conventional systems with more advanced analyzers. Growing demand for rapid and reliable diagnostic capabilities is expected to further accelerate adoption within this segment.

Test Type Segment Analysis: Laboratory Testing (Largest Segment) vs Point-of-care (POC) Testing (Fastest-Growing Segment)

The laboratory testing segment held the largest share of the CT/NG testing market, accounting for 70.37% in 2026. Laboratory-based testing remains the preferred approach because it provides high diagnostic accuracy, comprehensive testing capabilities, and the capacity to process large sample volumes efficiently. Advanced laboratory infrastructure, skilled personnel, and the widespread use of molecular diagnostic technologies continue to support the dominant position of this segment. Healthcare providers also rely on laboratory testing to ensure reliable confirmation of infections and appropriate clinical decision-making.

The point-of-care (POC) testing segment is anticipated to record the fastest growth as healthcare systems increasingly emphasize rapid diagnosis, immediate clinical decisions, and improved patient accessibility. Point-of-care testing enables healthcare professionals to deliver results quickly without depending on centralized laboratory infrastructure, supporting timely treatment and reducing follow-up delays. Rising demand for decentralized healthcare services and advancements in portable diagnostic technologies continue to drive the expansion of this segment.

Technology Segment Analysis: Polymerase Chain Reaction (Largest Segment) vs Isothermal Nucleic Acid Amplification Technology (Fastest-Growing Segment)

The polymerase chain reaction technology segment dominated the CT/NG testing market, accounting for 49.18% in 2026. Its leadership is supported by its high analytical sensitivity, strong specificity, and ability to accurately detect low concentrations of infectious genetic material. Polymerase chain reaction technology has become a widely adopted diagnostic method due to its reliability, standardized laboratory implementation, and compatibility with high-throughput testing platforms. Continued adoption of molecular diagnostics further reinforces the segment's dominant position.

The isothermal nucleic acid amplification technology segment is expected to witness the fastest growth as healthcare providers seek rapid molecular diagnostic methods that require simpler workflows and faster result generation. The technology enables efficient nucleic acid amplification without complex thermal cycling, making it particularly suitable for decentralized and point-of-care testing environments. Ongoing innovation in rapid diagnostic platforms and increasing demand for accessible molecular testing solutions are expected to support the continued growth of this segment.